Ruitai Biotechnology
A developer for ophthalmic regenerative medicine, specialising in the R&D and sale of repair materials and medical device products
About Ruitai Biotechnology
Established in 2011, Hangzhou Ruitai Biotechnology Co., Ltd. is a chemical manufacturer specializing in the development, production, and sale of a diverse portfolio of specialty ingredients. The company operates in several key markets, providing raw materials for the personal care, nutritional supplement, and pharmaceutical sectors. Its business model is centered on business-to-business (B2B) sales of these manufactured chemical products to other companies.
The company's product lines are segmented into distinct categories. For the personal care industry, it produces hair colorants and other cosmetic ingredients. It also manufactures a range of nutritional supplements and pharmaceutical intermediates, which are the foundational chemical compounds used in the production of finished drug products. This indicates a client base ranging from cosmetics corporations to pharmaceutical and nutraceutical companies. To support its production and quality claims, the company operates its own factory equipped with fermentation, extraction, and synthesis laboratories. Furthermore, Hangzhou Ruitai Biotechnology has implemented a quality management system that is certified to the GB/T 19001-2016/ISO 9001:2015 standard, underscoring its commitment to operational and product quality.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Dietary Supplements, Nutrition, Pharmaceutical, Hard Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2023 | $14M | $55M | Zhongda Venture Capital · well-known industrial capital · Green Pine Capital · HM Capital | ↗ |
| SERIES AEquity / VC | Apr 2022 | $0 | — | HM Capital | ↗ |
Growth signals
Latest recorded traffic for Ruitai Biotechnology is 190 monthly website visits, down 29.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ruitai Biotechnology in the Ningbo ecosystem
The Ruitai Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
HM Capital
Green Pine Capital- ZCZhongda Venture Capital
- WCwell-known industrial capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruitai Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruitai Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









